Scleroderma Clinical Trials

A listing of Scleroderma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
Featured trial
A trial evaluating TEPEZZA® in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

weeks (q3W) for 24 weeks in the treatment of participants with diffuse cutaneous systemic sclerosis (dcSSc).

  • 0 views
  • 20 May, 2022
  • 3 locations
Featured trial
Study to evaluate HZN-825 in patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

The goal is to determine the efficacy, safety and tolerability for 300 patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc) assigned to either one of 2 dose regimens of HZN-825

rheumatism
MRSS
raynaud's phenomenon
diffuse cutaneous systemic sclerosis
raynaud's syndrome
  • 10 views
  • 09 Jul, 2022
  • 48 locations
A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis

The purpose of this study is to determine whether oral temanogrel improves digital blood flow in participants with Raynaud's phenomenon secondary to systemic sclerosis (SSc-RP) as a potential

  • 9 views
  • 27 Jul, 2022
  • 6 locations
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with diffuse cutaneous Systemic Sclerosis (dcSSc).

  • 17 views
  • 07 Jul, 2022
  • 24 locations
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

To evaluate the efficacy of MT-7117 treatment in subjects with diffuse cutaneous systemic sclerosis (dcSSc) using the American College of Rheumatology Composite Response Index in Diffuse

  • 6 views
  • 11 Jul, 2022
  • 42 locations
Phase 2 Safety and Efficacy Study of PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (ATHENA-SSc-ILD)

The purpose of this study is to assess the safety and efficacy of PRA023 in participants with SSc-ILD .

progressive systemic sclerosis
interstitial lung disease
carbon monoxide
methotrexate
azathioprine
  • 0 views
  • 21 Jul, 2022
  • 11 locations
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

>Systemic Lupus Erythematosus (SLE) Rheumatoid Arthritis (RA) Multiple Sclerosis (MS) Systemic Sclerosis (SSc), and Pemphigus. This study will focus on 4

treatment regimen
SARS
hydroxychloroquine
mycophenolate
prednisone
  • 63 views
  • 24 Jul, 2022
  • 19 locations
Deployment o the Multidisciplinary Prospective Cohort Imminent (IMMINeNT)

Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and emotional repercussions. Beyond this burden, IMIDs share many common pathophysiological mechanisms and treatments, known as "targeted therapies". Despite …

disease or disorder
  • 0 views
  • 09 Jun, 2022
  • 1 location
Impact of Transcutaneous Auricular Vagus Nerve Stimulation on Digestive Symptoms in Systemic Sclerosis Systemic Sclerosis (AVADIS)

The purpose of this study is to assess the effect of transcutaneous auricular vagus nerve stimulation (ta-VNS) on gastrointestinal symptoms and quality of life in systemic sclerosis (SSc

  • 0 views
  • 02 Jun, 2022
Brentuximab Vedotin for Systemic Sclerosis (BRAVOS)

There is significant unmet need for effective treatment options for Diffuse Cutaneous Systemic Sclerosis (dcSSc). The present study will be a dose-escalation safety trial of brentuximab vedotin

mycophenolate
methotrexate
raynaud's phenomenon
diffuse cutaneous systemic sclerosis
immunosuppression
  • 722 views
  • 26 May, 2022
  • 8 locations